{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:52:59Z","timestamp":1790837579377,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-024-04748-y","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:29:07Z","timestamp":1730093347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link"],"prefix":"10.1007","volume":"39","author":[{"given":"Vahid Khaze","family":"Shahgoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Noorolyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahya","family":"Ahmadpour Youshanlui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Saeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Holmskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"7203","key":"4748_CR1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A et al (2008) Cancer-related inflammation. Nature 454(7203):436\u2013444","journal-title":"Nature"},{"issue":"23","key":"4748_CR2","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1038\/onc.2010.109","volume":"29","author":"S Danese","year":"2010","unstructured":"Danese S, Mantovani A (2010) Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 29(23):3313\u20133323","journal-title":"Oncogene"},{"issue":"12","key":"4748_CR3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/gutjnl-2011-300953","volume":"60","author":"S Danese","year":"2011","unstructured":"Danese S, Malesci A, Vetrano S (2011) Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut 60(12):1609\u20131610","journal-title":"Gut"},{"key":"4748_CR4","first-page":"503","volume-title":"Colorectal cancer in inflammatory bowel disease","author":"RW Leong","year":"2009","unstructured":"Leong RW, Koo JH (2009) Colorectal cancer in inflammatory bowel disease. Blackwell Publishing Asia Melbourne, Australia, pp 503\u2013505"},{"issue":"3","key":"4748_CR5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4251\/wjgo.v14.i3.547","volume":"14","author":"S Majumder","year":"2022","unstructured":"Majumder S et al (2022) Inflammatory bowel disease-related colorectal cancer: past, present and future perspectives. World J Gastroint Oncol 14(3):547","journal-title":"World J Gastroint Oncol"},{"issue":"3","key":"4748_CR6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","volume":"162","author":"SC Shah","year":"2022","unstructured":"Shah SC, Itzkowitz SH (2022) Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology 162(3):715-730.e3","journal-title":"Gastroenterology"},{"issue":"20","key":"4748_CR7","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","volume":"22","author":"JE Axelrad","year":"2016","unstructured":"Axelrad JE, Lichtiger S, Yajnik V (2016) Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 22(20):4794","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4748_CR8","doi-asserted-by":"crossref","first-page":"G7","DOI":"10.1152\/ajpgi.00079.2004","volume":"287","author":"SH Itzkowitz","year":"2004","unstructured":"Itzkowitz SH, Yio X (2004) Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287(1):G7\u2013G17","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"4748_CR9","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","volume":"138","author":"J Terzi\u0107","year":"2010","unstructured":"Terzi\u0107 J et al (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114.e5","journal-title":"Gastroenterology"},{"issue":"5","key":"4748_CR10","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"key":"4748_CR11","first-page":"118","volume":"13","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment and its impact on cancer development. Infect Inflam 13:118\u2013137","journal-title":"Infect Inflam"},{"issue":"4","key":"4748_CR12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrc1046","volume":"3","author":"SP Hussain","year":"2003","unstructured":"Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3(4):276\u2013285","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4748_CR13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883\u2013899","journal-title":"Cell"},{"issue":"3","key":"4748_CR14","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/cancers13030574","volume":"13","author":"C Fiorillo","year":"2021","unstructured":"Fiorillo C et al (2021) Challenges in Crohn\u2019s disease management after gastrointestinal cancer diagnosis. Cancers 13(3):574","journal-title":"Cancers"},{"issue":"4","key":"4748_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/imt.12.15","volume":"4","author":"MJ Waldner","year":"2012","unstructured":"Waldner MJ, Neurath MF (2012) Potential avenues for immunotherapy of colitis-associated neoplasia. Immunotherapy 4(4):397\u2013405","journal-title":"Immunotherapy"},{"key":"4748_CR16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10620-015-3646-4","volume":"60","author":"M Yashiro","year":"2015","unstructured":"Yashiro M (2015) Molecular alterations of colorectal cancer with inflammatory bowel disease. Dig Dis Sci 60:2251\u20132263","journal-title":"Dig Dis Sci"},{"issue":"6","key":"4748_CR17","first-page":"903","volume":"33","author":"H Nakase","year":"2021","unstructured":"Nakase H et al (2021) Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc 33(6):903\u2013911","journal-title":"Dig Endosc"},{"key":"4748_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.dld.2024.04.005","volume":"56","author":"Y Maeda","year":"2024","unstructured":"Maeda Y et al (2024) Artificial intelligence-assisted colonoscopy to identify histologic remission and predict the outcomes of patients with ulcerative colitis: a systematic review. Dig Liver Dis 56:1119\u20131125","journal-title":"Dig Liver Dis"},{"issue":"24","key":"4748_CR19","doi-asserted-by":"crossref","first-page":"6131","DOI":"10.3390\/cancers14246131","volume":"14","author":"R Ephraim","year":"2022","unstructured":"Ephraim R et al (2022) Cancer immunotherapy: the checkpoint between chronic colitis and colorectal cancer. Cancers 14(24):6131","journal-title":"Cancers"},{"issue":"7","key":"4748_CR20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.trecan.2021.02.005","volume":"7","author":"AE Chang","year":"2021","unstructured":"Chang AE et al (2021) Targeting the gut microbiome to mitigate immunotherapy-induced colitis in cancer. Trends in Cancer 7(7):583\u2013593","journal-title":"Trends in Cancer"},{"issue":"8","key":"4748_CR21","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.3390\/cancers15082389","volume":"15","author":"OM Nardone","year":"2023","unstructured":"Nardone OM et al (2023) Inflammation-driven colorectal cancer associated with colitis: from pathogenesis to changing therapy. Cancers 15(8):2389","journal-title":"Cancers"},{"issue":"1","key":"4748_CR22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-023-00492-0","volume":"12","author":"RW Zhou","year":"2023","unstructured":"Zhou RW et al (2023) Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis 12(1):48","journal-title":"Oncogenesis"},{"issue":"5","key":"4748_CR23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.dld.2021.01.012","volume":"53","author":"MC Fantini","year":"2021","unstructured":"Fantini MC, Guadagni I (2021) From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: pathogenesis and impact of current therapies. Dig Liver Dis 53(5):558\u2013565","journal-title":"Dig Liver Dis"},{"key":"4748_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2017.04.003","volume":"32","author":"M Kang","year":"2017","unstructured":"Kang M, Martin A (2017) Microbiome and colorectal cancer: unraveling host-microbiota interactions in colitis-associated colorectal cancer development. Semin Immunol 32:3\u201313","journal-title":"Semin Immunol"},{"issue":"7203","key":"4748_CR25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A et al (2008) Cancer-related inflammation. Nature 454(7203):436\u2013444","journal-title":"Nature"},{"issue":"14","key":"4748_CR26","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.3390\/cancers14143333","volume":"14","author":"F Liotti","year":"2022","unstructured":"Liotti F et al (2022) The impact of resolution of inflammation on tumor microenvironment: exploring new ways to control cancer progression. Cancers (Basel) 14(14):3333","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4748_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI (2019) Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 51(1):27\u201341","journal-title":"Immunity"},{"issue":"11","key":"4748_CR28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H et al (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14(11):736\u2013746","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4748_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC et al (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(1):1\u201320","journal-title":"Biochem J"},{"issue":"1","key":"4748_CR30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","volume":"10","author":"T Wang","year":"2004","unstructured":"Wang T et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48\u201354","journal-title":"Nat Med"},{"issue":"3","key":"4748_CR31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/cancers14030552","volume":"14","author":"B Wu","year":"2022","unstructured":"Wu B, Sodji QH, Oyelere AK (2022) Inflammation, fibrosis and cancer: mechanisms, therapeutic options and challenges. Cancers 14(3):552","journal-title":"Cancers"},{"issue":"12","key":"4748_CR32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","volume":"25","author":"D Furman","year":"2019","unstructured":"Furman D et al (2019) Chronic inflammation in the etiology of disease across the life span. Nat Med 25(12):1822\u20131832","journal-title":"Nat Med"},{"issue":"11","key":"4748_CR33","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.cellsig.2014.07.035","volume":"26","author":"K Bhatelia","year":"2014","unstructured":"Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26(11):2350\u20132357","journal-title":"Cell Signal"},{"issue":"3","key":"4748_CR34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbrc.2015.10.133","volume":"472","author":"S Suman","year":"2016","unstructured":"Suman S et al (2016) Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer. Biochem Biophys Res Commun 472(3):401\u2013409","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"4748_CR35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.coph.2009.06.010","volume":"9","author":"MM Abdel-Latif","year":"2009","unstructured":"Abdel-Latif MM et al (2009) Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 9(4):396\u2013404","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"4748_CR36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10555-022-10026-6","volume":"41","author":"T Sharma","year":"2022","unstructured":"Sharma T et al (2022) Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer Metastasis Rev 41(2):281\u2013299","journal-title":"Cancer Metastasis Rev"},{"issue":"23","key":"4748_CR37","doi-asserted-by":"crossref","first-page":"12739","DOI":"10.3390\/ijms222312739","volume":"22","author":"S Frigerio","year":"2021","unstructured":"Frigerio S et al (2021) The role of the immune system in IBD-associated colorectal cancer: from pro to anti-tumorigenic mechanisms. Int J Mol Sci 22(23):12739","journal-title":"Int J Mol Sci"},{"key":"4748_CR38","doi-asserted-by":"crossref","first-page":"722999","DOI":"10.3389\/fonc.2021.722999","volume":"11","author":"R Chavez-Dominguez","year":"2021","unstructured":"Chavez-Dominguez R et al (2021) Old and new players of inflammation and their relationship with cancer development. Front Oncol 11:722999","journal-title":"Front Oncol"},{"issue":"8","key":"4748_CR39","doi-asserted-by":"crossref","first-page":"a028662","DOI":"10.1101\/cshperspect.a028662","volume":"10","author":"MR Galdiero","year":"2018","unstructured":"Galdiero MR, Marone G, Mantovani A (2018) Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 10(8):a028662","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"4748_CR40","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","volume":"9","author":"L Chen","year":"2018","unstructured":"Chen L et al (2018) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9(6):7204","journal-title":"Oncotarget"},{"issue":"8","key":"4748_CR41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1349-7006.2008.00853.x","volume":"99","author":"M Ono","year":"2008","unstructured":"Ono M (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8):1501\u20131506","journal-title":"Cancer Sci"},{"issue":"11","key":"4748_CR42","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/sj.bjc.6601705","volume":"90","author":"E Lin","year":"2004","unstructured":"Lin E, Pollard J (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90(11):2053\u20132058","journal-title":"Br J Cancer"},{"issue":"1","key":"4748_CR43","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12935-021-02140-2","volume":"21","author":"M Soutto","year":"2021","unstructured":"Soutto M et al (2021) NF-kB-dependent activation of STAT3 by H. pylori is suppressed by TFF1. Cancer Cell Int 21(1):444","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4748_CR44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/jcm11030866","volume":"11","author":"K Mary\u0144czak","year":"2022","unstructured":"Mary\u0144czak K et al (2022) Colitis-associated colorectal cancer in patients with inflammatory bowel diseases in a tertiary referral center: a propensity score matching analysis. J Clin Med 11(3):866","journal-title":"J Clin Med"},{"key":"4748_CR45","first-page":"1","volume":"2013","author":"N Qu","year":"2013","unstructured":"Qu N et al (2013) Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. J Immunol Res 2013:1\u201313","journal-title":"J Immunol Res"},{"issue":"1","key":"4748_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H et al (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6(1):263","journal-title":"Signal Transduct Target Ther"},{"key":"4748_CR47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3389\/fmolb.2020.00122","volume":"7","author":"N Pe\u0107ina-\u0160laus","year":"2020","unstructured":"Pe\u0107ina-\u0160laus N et al (2020) Mismatch repair pathway, genome stability and cancer. Front Mol Biosci 7:122","journal-title":"Front Mol Biosci"},{"issue":"4","key":"4748_CR48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/ijms19040970","volume":"19","author":"AK Basu","year":"2018","unstructured":"Basu AK (2018) DNA damage, mutagenesis and cancer. Int J Mol Sci 19(4):970","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4748_CR49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/path.2803","volume":"223","author":"M Allen","year":"2011","unstructured":"Allen M, Louise Jones J (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223(2):163\u2013177","journal-title":"J Pathol"},{"issue":"8","key":"4748_CR50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA et al (2022) Cytokine-and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun 42(8):689\u2013715","journal-title":"Cancer Commun"},{"issue":"5","key":"4748_CR51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M (2018) NF-\u03baB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309\u2013324","journal-title":"Nat Rev Immunol"},{"key":"4748_CR52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trsl.2018.02.002","volume":"197","author":"M Patel","year":"2018","unstructured":"Patel M et al (2018) NF-\u03baB pathways in the development and progression of colorectal cancer. Transl Res 197:43\u201356","journal-title":"Transl Res"},{"key":"4748_CR53","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","volume":"9","author":"D Aguilar-Cazares","year":"2019","unstructured":"Aguilar-Cazares D et al (2019) Contribution of angiogenesis to inflammation and cancer. Front Oncol 9:1399","journal-title":"Front Oncol"},{"issue":"2","key":"4748_CR54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41419-021-03426-z","volume":"12","author":"L Klemke","year":"2021","unstructured":"Klemke L et al (2021) Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis 12(2):155","journal-title":"Cell Death Dis"},{"issue":"1","key":"4748_CR55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","volume":"16","author":"TL Whiteside","year":"2006","unstructured":"Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16(1):3\u201315","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"4748_CR56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W et al (2019) KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35(4):559\u2013572","journal-title":"Cancer Cell"},{"issue":"10","key":"4748_CR57","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s41577-021-00534-x","volume":"21","author":"M Schmitt","year":"2021","unstructured":"Schmitt M, Greten FR (2021) The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 21(10):653\u2013667","journal-title":"Nat Rev Immunol"},{"key":"4748_CR58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3389\/fimmu.2019.00729","volume":"10","author":"AM Mileo","year":"2019","unstructured":"Mileo AM, Nistic\u00f2 P, Miccadei S (2019) Polyphenols: immunomodulatory and therapeutic implication in colorectal cancer. Front Immunol 10:729","journal-title":"Front Immunol"},{"issue":"5","key":"4748_CR59","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1002\/jcp.27415","volume":"234","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S et al (2019) The role of microRNAs involved in PI3-kinase signaling pathway in colorectal cancer. J Cell Physiol 234(5):5664\u20135673","journal-title":"J Cell Physiol"},{"issue":"5","key":"4748_CR60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10350-003-0111-9","volume":"47","author":"T Asano","year":"2004","unstructured":"Asano T, McLeod R (2004) Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum 47(5):665\u2013673","journal-title":"Dis Colon Rectum"},{"key":"4748_CR61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-4939-8885-3_13","volume":"1884","author":"L Santiago","year":"2019","unstructured":"Santiago L et al (2019) Mouse model of colitis-associated colorectal cancer (CAC): isolation and characterization of mucosal-associated lymphoid cells. Methods Mol Biol 1884:189\u2013202","journal-title":"Methods Mol Biol"},{"issue":"15","key":"4748_CR62","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.3390\/cancers15153803","volume":"15","author":"B Neri","year":"2023","unstructured":"Neri B et al (2023) Mucinous and signet-ring cell colonic adenocarcinoma in inflammatory bowel disease: a case\u2013control study. Cancers 15(15):3803","journal-title":"Cancers"},{"issue":"4","key":"4748_CR63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","volume":"48","author":"J Eaden","year":"2001","unstructured":"Eaden J, Abrams K, Mayberry J (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4):526\u2013535","journal-title":"Gut"},{"issue":"3","key":"4748_CR64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccr.2004.08.011","volume":"6","author":"D Wang","year":"2004","unstructured":"Wang D et al (2004) Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor \u03b4. Cancer Cell 6(3):285\u2013295","journal-title":"Cancer Cell"},{"issue":"2","key":"4748_CR65","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.gastro.2012.04.016","volume":"143","author":"T Jess","year":"2012","unstructured":"Jess T et al (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143(2):375-381.e1","journal-title":"Gastroenterology"},{"issue":"6","key":"4748_CR66","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/gutjnl-2018-316191","volume":"68","author":"A-M Baker","year":"2019","unstructured":"Baker A-M et al (2019) Evolutionary history of human colitis-associated colorectal cancer. Gut 68(6):985\u2013995","journal-title":"Gut"},{"issue":"7","key":"4748_CR67","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ajg.2015.65","volume":"110","author":"C-HR Choi","year":"2015","unstructured":"Choi C-HR et al (2015) Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol 110(7):1022","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4748_CR68","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2015.12.036","volume":"150","author":"AI Robles","year":"2016","unstructured":"Robles AI et al (2016) Whole-exome sequencing analyses of inflammatory bowel disease\u2212 associated colorectal cancers. Gastroenterology 150(4):931\u2013943","journal-title":"Gastroenterology"},{"issue":"2","key":"4748_CR69","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.gastro.2016.04.001","volume":"151","author":"R Yaeger","year":"2016","unstructured":"Yaeger R et al (2016) Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology 151(2):278-287.e6","journal-title":"Gastroenterology"},{"issue":"6","key":"4748_CR70","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/ijms18061284","volume":"18","author":"K Kobayashi","year":"2017","unstructured":"Kobayashi K et al (2017) p53 expression as a diagnostic biomarker in ulcerative colitis-associated cancer. Int J Mol Sci 18(6):1284","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4748_CR71","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrgastro.2017.1","volume":"14","author":"C-HR Choi","year":"2017","unstructured":"Choi C-HR et al (2017) Clonal evolution of colorectal cancer in IBD. Nat Rev Gastroenterol Hepatol 14(4):218\u2013229","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4748_CR72","first-page":"7","volume":"21","author":"Y Tanimura","year":"2021","unstructured":"Tanimura Y et al (2021) Long-term model of colitis-associated colorectal cancer suggests tumor spread mechanism and nature of cancer stem cells. Oncol Lett 21(1):7","journal-title":"Oncol Lett"},{"key":"4748_CR73","doi-asserted-by":"crossref","first-page":"112600","DOI":"10.1016\/j.jep.2020.112600","volume":"252","author":"X Wang","year":"2020","unstructured":"Wang X et al (2020) Protective effect of ShaoYao decoction on colitis-associated colorectal cancer by inducing Nrf2 signaling pathway. J Ethnopharmacol 252:112600","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"4748_CR74","doi-asserted-by":"crossref","first-page":"166288","DOI":"10.1016\/j.bbadis.2021.166288","volume":"1868","author":"MA Marie","year":"2022","unstructured":"Marie MA et al (2022) GPR65 (TDAG8) inhibits intestinal inflammation and colitis-associated colorectal cancer development in experimental mouse models. Biochim Biophys Acta Mol Basis Dis 1868(1):166288","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"4748_CR75","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","volume":"24","author":"A Saez","year":"2023","unstructured":"Saez A et al (2023) Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci 24(2):1526","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4748_CR76","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3390\/cells10113211","volume":"10","author":"L Garc\u00eda-L\u00f3pez","year":"2021","unstructured":"Garc\u00eda-L\u00f3pez L et al (2021) A blueprint for cancer-related inflammation and host innate immunity. Cells 10(11):3211","journal-title":"Cells"},{"issue":"1","key":"4748_CR77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri2891","volume":"11","author":"M Saleh","year":"2011","unstructured":"Saleh M, Trinchieri G (2011) Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11(1):9\u201320","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4748_CR78","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.21873\/anticanres.14556","volume":"40","author":"A Angelou","year":"2020","unstructured":"Angelou A et al (2020) The interplay between innate immunity (TLR-4) and sCD40L in the context of an animal model of colitis-associated cancer. Anticancer Res 40(10):5457\u20135462","journal-title":"Anticancer Res"},{"issue":"2","key":"4748_CR79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrgastro.2009.232","volume":"7","author":"RD Cohen","year":"2010","unstructured":"Cohen RD (2010) The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 7(2):103\u2013109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4748_CR80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrgastro.2009.221","volume":"7","author":"S De Silva","year":"2010","unstructured":"De Silva S, Devlin S, Panaccione R (2010) Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 7(2):93\u2013101","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4748_CR81","doi-asserted-by":"crossref","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"L-Q Fu","year":"2020","unstructured":"Fu L-Q et al (2020) The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol 353:104119","journal-title":"Cell Immunol"},{"issue":"10","key":"4748_CR82","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1002\/cam4.2327","volume":"8","author":"J Wang","year":"2019","unstructured":"Wang J et al (2019) Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med 8(10):4709\u20134721","journal-title":"Cancer Med"},{"issue":"5","key":"4748_CR83","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrgastro.2009.44","volume":"6","author":"LA Feagins","year":"2009","unstructured":"Feagins LA, Souza RF, Spechler SJ (2009) Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6(5):297\u2013305","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4748_CR84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12307-010-0052-5","volume":"4","author":"M Erreni","year":"2011","unstructured":"Erreni M, Mantovani A, Allavena P (2011) Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 4(2):141\u2013154","journal-title":"Cancer Microenviron"},{"issue":"11","key":"4748_CR85","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A et al (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549\u2013555","journal-title":"Trends Immunol"},{"key":"4748_CR86","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3389\/fimmu.2020.01526","volume":"11","author":"I Sieminska","year":"2020","unstructured":"Sieminska I, Baran J (2020) Myeloid-derived suppressor cells in colorectal cancer. Front Immunol 11:1526","journal-title":"Front Immunol"},{"issue":"2","key":"4748_CR87","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19(2):108\u2013119","journal-title":"Nat Immunol"},{"issue":"5","key":"4748_CR88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","volume":"24","author":"H Katoh","year":"2013","unstructured":"Katoh H et al (2013) CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24(5):631\u2013644","journal-title":"Cancer Cell"},{"issue":"11","key":"4748_CR89","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski MM et al (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9(11):1225\u20131235","journal-title":"Nat Immunol"},{"issue":"7","key":"4748_CR90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1080\/00365520410005603","volume":"39","author":"H Ytting","year":"2004","unstructured":"Ytting H et al (2004) Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 39(7):674\u2013679","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"4748_CR91","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/diagnostics10121077","volume":"10","author":"M Beitia","year":"2020","unstructured":"Beitia M et al (2020) The activation of prothrombin seems to play an earlier role than the complement system in the progression of colorectal cancer: a mass spectrometry evaluation. Diagnostics 10(12):1077","journal-title":"Diagnostics"},{"issue":"9","key":"4748_CR92","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3390\/cancers12092626","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y et al (2020) Targeting myeloid-derived suppressor cells in cancer immunotherapy. Cancers (Basel) 12(9):2626","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4748_CR93","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.08.056","volume":"155","author":"CG Hurtado","year":"2018","unstructured":"Hurtado CG et al (2018) Roles for interleukin 17 and adaptive immunity in pathogenesis of colorectal cancer. Gastroenterology 155(6):1706\u20131715","journal-title":"Gastroenterology"},{"issue":"2","key":"4748_CR94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3748\/wjg.v19.i2.174","volume":"19","author":"F Grizzi","year":"2013","unstructured":"Grizzi F et al (2013) Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol 19(2):174","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4748_CR95","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1073\/pnas.0334211100","volume":"100","author":"D Bagga","year":"2003","unstructured":"Bagga D et al (2003) Differential effects of prostaglandin derived from \u03c9-6 and \u03c9-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci 100(4):1751\u20131756","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"4748_CR96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/gastro\/goaa060","volume":"9","author":"P Sun","year":"2021","unstructured":"Sun P et al (2021) lncRNA-PACER upregulates COX-2 and PGE2 through the NF-\u03baB pathway to promote the proliferation and invasion of colorectal-cancer cells. Gastroenterol Rep 9(3):257\u2013268","journal-title":"Gastroenterol Rep"},{"issue":"4","key":"4748_CR97","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G et al (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39(4):782\u2013795","journal-title":"Immunity"},{"key":"4748_CR98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M et al (2020) In vivo CD4+ T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol 38:705\u2013725","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"4748_CR99","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"issue":"34\u201335","key":"4748_CR100","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1055\/s-2007-984966","volume":"132","author":"S Schreiber","year":"2007","unstructured":"Schreiber S (2007) Crohn\u2019s disease\u2013infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment. Dtsch Med Wochenschr 132(34\u201335):1770\u20131774","journal-title":"Dtsch Med Wochenschr"},{"issue":"10","key":"4748_CR101","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/1940-6207.CAPR-09-0272","volume":"3","author":"YJ Kim","year":"2010","unstructured":"Kim YJ et al (2010) Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila) 3(10):1314\u20131333","journal-title":"Cancer Prev Res (Phila)"},{"issue":"13","key":"4748_CR102","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2021.2651","volume":"325","author":"DJ Kerr","year":"2021","unstructured":"Kerr DJ, Chamberlain S, Kerr RS (2021) Celecoxib for stage III colon cancer. JAMA 325(13):1257\u20131258","journal-title":"JAMA"},{"issue":"24","key":"4748_CR103","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.3390\/ijms20246254","volume":"20","author":"R Mizuno","year":"2019","unstructured":"Mizuno R, Kawada K, Sakai Y (2019) Prostaglandin E2\/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci 20(24):6254","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4748_CR104","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1021\/acs.jmedchem.0c01799","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu Z et al (2021) Small-molecule inhibitors targeting the canonical WNT signaling pathway for the treatment of cancer. J Med Chem 64(8):4257\u20134288","journal-title":"J Med Chem"},{"key":"4748_CR105","first-page":"4479","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz S et al (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479\u20134499","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"4748_CR106","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T et al (2022) Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol 23(9):1189\u20131200","journal-title":"Lancet Oncol"},{"issue":"6","key":"4748_CR107","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel P et al (2021) The present and future of PI3K inhibitors for cancer therapy. Nat Cancer 2(6):587\u2013597","journal-title":"Nat Cancer"},{"issue":"1","key":"4748_CR108","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"4748_CR109","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41575-023-00756-5","volume":"20","author":"E Kotsiliti","year":"2023","unstructured":"Kotsiliti E (2023) MAPK inhibition in BRAF(V600E) CRC. Nat Rev Gastroenterol Hepatol 20(4):201","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4748_CR110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian J et al (2023) Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial. Nat Med 29(2):458\u2013466","journal-title":"Nat Med"},{"issue":"2","key":"4748_CR111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41419-017-0176-3","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X et al (2018) Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6\/JAK2\/STAT3 signaling. Cell Death Dis 9(2):25","journal-title":"Cell Death Dis"},{"key":"4748_CR112","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.2147\/OTT.S278013","volume":"13","author":"Y Lin","year":"2020","unstructured":"Lin Y et al (2020) Progress in understanding the IL-6\/STAT3 pathway in colorectal cancer. OncoTargets Ther 13:13023\u201313032","journal-title":"OncoTargets Ther"},{"key":"4748_CR113","doi-asserted-by":"crossref","first-page":"760971","DOI":"10.3389\/fonc.2021.760971","volume":"11","author":"J Xu","year":"2021","unstructured":"Xu J et al (2021) IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol 11:760971","journal-title":"Front Oncol"},{"issue":"1","key":"4748_CR114","first-page":"1","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T et al (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2(1):1\u20139","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"4748_CR115","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/ibd\/izz149","volume":"25","author":"D Yao","year":"2019","unstructured":"Yao D et al (2019) Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer. Inflamm Bowel Dis 25(10):1595\u20131602","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4748_CR116","first-page":"21","volume":"2","author":"E Viennois","year":"2013","unstructured":"Viennois E, Chen F, Merlin D (2013) NF-\u03baB pathway in colitis-associated cancers. Transl Gastrointest Cancer 2(1):21","journal-title":"Transl Gastrointest Cancer"},{"issue":"4","key":"4748_CR117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/mi.6.4.6","volume":"6","author":"R Rajakariar","year":"2006","unstructured":"Rajakariar R, Yaqoob MM, Gilroy DW (2006) COX-2 in inflammation and resolution. Mol Interven 6(4):199","journal-title":"Mol Interven"},{"issue":"6","key":"4748_CR118","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/onc.2009.421","volume":"29","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN (2010) The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29(6):781\u2013788","journal-title":"Oncogene"},{"issue":"1","key":"4748_CR119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J et al (2022) Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther 7(1):3","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4748_CR120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","volume":"13","author":"M Kahn","year":"2014","unstructured":"Kahn M (2014) Can we safely target the WNT pathway? Nat Rev Drug Discovery 13(7):513\u2013532","journal-title":"Nat Rev Drug Discovery"},{"issue":"9","key":"4748_CR121","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3390\/cells9092125","volume":"9","author":"J Bian","year":"2020","unstructured":"Bian J et al (2020) Transcriptional regulation of Wnt\/\u03b2-catenin pathway in colorectal cancer. Cells 9(9):2125","journal-title":"Cells"},{"issue":"1","key":"4748_CR122","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1038\/cddis.2013.515","volume":"5","author":"J Mao","year":"2014","unstructured":"Mao J et al (2014) Roles of Wnt\/\u03b2-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment. Cell Death Dis 5(1):e1039\u2013e1039","journal-title":"Cell Death Dis"},{"issue":"1","key":"4748_CR123","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.taap.2012.04.014","volume":"262","author":"X Wang","year":"2012","unstructured":"Wang X et al (2012) Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt\/\u03b2-catenin signaling pathway. Toxicol Appl Pharmacol 262(1):11\u201321","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"4748_CR124","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/jcb.25496","volume":"117","author":"V Syed","year":"2016","unstructured":"Syed V (2016) TGF-\u03b2 signaling in cancer. J Cell Biochem 117(6):1279\u20131287","journal-title":"J Cell Biochem"},{"issue":"5","key":"4748_CR125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ccr.2012.08.013","volume":"22","author":"A Calon","year":"2012","unstructured":"Calon A et al (2012) Dependency of colorectal cancer on a TGF-\u03b2-driven program in stromal cells for metastasis initiation. Cancer Cell 22(5):571\u2013584","journal-title":"Cancer Cell"},{"issue":"23","key":"4748_CR126","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.3390\/ijms20235822","volume":"20","author":"Y Itatani","year":"2019","unstructured":"Itatani Y, Kawada K, Sakai Y (2019) Transforming growth factor-\u03b2 signaling pathway in colorectal cancer and its tumor microenvironment. Int J Mol Sci 20(23):5822","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4748_CR127","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","volume":"47","author":"N Jiang","year":"2020","unstructured":"Jiang N et al (2020) Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep 47(6):4587\u20134629","journal-title":"Mol Biol Rep"},{"issue":"19","key":"4748_CR128","doi-asserted-by":"crossref","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani C et al (2021) Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci 22(19):10260","journal-title":"Int J Mol Sci"},{"issue":"21","key":"4748_CR129","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.3390\/cancers13215565","volume":"13","author":"C-Y Lai","year":"2021","unstructured":"Lai C-Y et al (2021) MicroRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K\/AKT, STAT3, and PDCD4\/TNF-\u03b1 signaling pathways in zebrafish. Cancers 13(21):5565","journal-title":"Cancers"},{"issue":"3","key":"4748_CR130","first-page":"1997","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ et al (2020) ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med 19(3):1997\u20132007","journal-title":"Exp Ther Med"},{"issue":"3","key":"4748_CR131","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/ijms21031102","volume":"21","author":"S Lee","year":"2020","unstructured":"Lee S, Rauch J, Kolch W (2020) Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 21(3):1102","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4748_CR132","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2014.02.019","volume":"25","author":"J Gupta","year":"2014","unstructured":"Gupta J et al (2014) Dual function of p38\u03b1 MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. Cancer Cell 25(4):484\u2013500","journal-title":"Cancer Cell"},{"key":"4748_CR133","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","volume":"15","author":"GA Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves GA, Paiva RD (2017) Gene therapy: advances, challenges and perspectives. Einstein (Sao Paulo) 15:369\u2013375","journal-title":"Einstein (Sao Paulo)"},{"issue":"282","key":"4748_CR134","first-page":"20143003","volume":"2015","author":"M Collins","year":"1821","unstructured":"Collins M, Thrasher A (1821) Gene therapy: progress and predictions. Proc R Soc B Biol Sci 2015(282):20143003","journal-title":"Proc R Soc B Biol Sci"},{"issue":"6372","key":"4748_CR135","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar CE et al (2018) Gene therapy comes of age. Science 359(6372):eaan4672","journal-title":"Science"},{"key":"4748_CR136","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.biotechadv.2019.107502","volume":"40","author":"C-C Ma","year":"2020","unstructured":"Ma C-C et al (2020) The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv 40:107502","journal-title":"Biotechnol Adv"},{"issue":"8","key":"4748_CR137","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1147","volume":"3","author":"D Kerr","year":"2003","unstructured":"Kerr D (2003) Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 3(8):615\u2013622","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4748_CR138","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 5(1):22","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"4748_CR139","first-page":"4968","volume":"62","author":"SO Freytag","year":"2002","unstructured":"Freytag SO et al (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Can Res 62(17):4968\u20134976","journal-title":"Can Res"},{"issue":"2","key":"4748_CR140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom K (2018) Viral vectors in gene therapy. Diseases 6(2):42","journal-title":"Diseases"},{"issue":"9","key":"4748_CR141","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543776.2016.1211640","volume":"26","author":"SA Navarro","year":"2016","unstructured":"Navarro SA et al (2016) Cancer suicide gene therapy: a patent review. Expert Opin Ther Pat 26(9):1095\u20131104","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"4748_CR142","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2012.05.023","volume":"324","author":"S Duarte","year":"2012","unstructured":"Duarte S et al (2012) Suicide gene therapy in cancer: where do we stand now? Cancer Lett 324(2):160\u2013170","journal-title":"Cancer Lett"},{"issue":"1","key":"4748_CR143","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","volume":"3","author":"S Colak","year":"2017","unstructured":"Colak S, Ten Dijke P (2017) Targeting TGF-\u03b2 signaling in cancer. Trends Cancer 3(1):56\u201371","journal-title":"Trends Cancer"},{"issue":"1","key":"4748_CR144","doi-asserted-by":"crossref","first-page":"188491","DOI":"10.1016\/j.bbcan.2020.188491","volume":"1875","author":"S Toden","year":"2021","unstructured":"Toden S, Zumwalt TJ, Goel A (2021) Non-coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer 1875(1):188491","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"4748_CR145","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y et al (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904\u2013910","journal-title":"Cancer Treat Rev"},{"key":"4748_CR146","doi-asserted-by":"crossref","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","volume":"9","author":"TR Damase","year":"2021","unstructured":"Damase TR et al (2021) The limitless future of RNA therapeutics. Front Bioeng Biotechnol 9:628137","journal-title":"Front Bioeng Biotechnol"},{"issue":"14","key":"4748_CR147","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3390\/ijms21145009","volume":"21","author":"C Barbari","year":"2020","unstructured":"Barbari C et al (2020) Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci 21(14):5009","journal-title":"Int J Mol Sci"},{"key":"4748_CR148","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","volume":"51","author":"T Sato","year":"2011","unstructured":"Sato T et al (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51:170\u2013182","journal-title":"Immunol Res"},{"issue":"8","key":"4748_CR149","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14728222.2019.1636034","volume":"23","author":"H Ungefroren","year":"2019","unstructured":"Ungefroren H (2019) Blockade of TGF-\u03b2 signaling: a potential target for cancer immunotherapy? Expert Opin Ther Targets 23(8):679\u2013693","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"4748_CR150","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4049\/jimmunol.164.6.3112","volume":"164","author":"II Narvaiza","year":"2000","unstructured":"Narvaiza II et al (2000) Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-\u03b3-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164(6):3112\u20133122","journal-title":"J Immunol"},{"issue":"23","key":"4748_CR151","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/sj.gt.3302100","volume":"10","author":"Y Saito","year":"2003","unstructured":"Saito Y et al (2003) Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Ther 10(23):1961\u20131969","journal-title":"Gene Ther"},{"issue":"12","key":"4748_CR152","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/bies.201500093","volume":"37","author":"Y Liu","year":"2015","unstructured":"Liu Y et al (2015) Targeting tumor suppressor genes for cancer therapy. BioEssays 37(12):1277\u20131286","journal-title":"BioEssays"},{"issue":"1","key":"4748_CR153","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1389450114666140106101412","volume":"15","author":"B Hong","year":"2014","unstructured":"Hong B et al (2014) Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 15(1):80\u201389","journal-title":"Curr Drug Targets"},{"issue":"3","key":"4748_CR154","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.hoc.2022.03.001","volume":"36","author":"S Piawah","year":"2022","unstructured":"Piawah S et al (2022) The gut microbiome in colorectal cancer. Hematol Oncol Clin North Am 36(3):491\u2013506","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"4748_CR155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41575-019-0209-8","volume":"16","author":"SH Wong","year":"2019","unstructured":"Wong SH, Yu J (2019) Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 16(11):690\u2013704","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4748_CR156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-021-00381-4","volume":"16","author":"A Shariati","year":"2021","unstructured":"Shariati A et al (2021) Association between colorectal cancer and Fusobacterium nucleatum and Bacteroides fragilis bacteria in Iranian patients: a preliminary study. Infect Agents Cancer 16(1):1\u201310","journal-title":"Infect Agents Cancer"},{"key":"4748_CR157","first-page":"188494","volume":"1","author":"A Badgeley","year":"1875","unstructured":"Badgeley A et al (1875) (2021) Effect of probiotics and gut microbiota on anti-cancer drugs: mechanistic perspectives. Biochim Biophys Acta Rev Cancer 1:188494","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"4748_CR158","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jfda.2018.12.011","volume":"27","author":"C-J Chang","year":"2019","unstructured":"Chang C-J et al (2019) Next generation probiotics in disease amelioration. J Food Drug Anal 27(3):615\u2013622","journal-title":"J Food Drug Anal"},{"key":"4748_CR159","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcancer.2019.05.001","volume":"64","author":"MS Nadeem","year":"2020","unstructured":"Nadeem MS et al (2020) Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol 64:51\u201360","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"4748_CR160","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjab215","volume":"16","author":"B Sensi","year":"2022","unstructured":"Sensi B et al (2022) Long-term oncological outcome of segmental versus extended colectomy for colorectal cancer in Crohn\u2019s disease: results from an international multicentre study. J Crohns Colitis 16(6):954\u2013962","journal-title":"J Crohns Colitis"},{"issue":"12","key":"4748_CR161","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/ecco-jcc\/jjaa107","volume":"14","author":"A Frontali","year":"2020","unstructured":"Frontali A et al (2020) Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis? An international multicentric retrospective study in 72 patients. J Crohns Colitis 14(12):1687\u20131692","journal-title":"J Crohns Colitis"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04748-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:04:22Z","timestamp":1736345062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04748-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":161,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4748"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04748-y","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"22 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"173"}}